Optimal dose for renoprotection by the angiotensin II receptor blocker candesartan in patients with type 2 diabetes and nephropathy.

被引：0
|
作者：
Rossing, K
Christensen, PK
Jacobsen, PK
Hansen, BV
Parving, HH
机构：
[1] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[2] Univ Aarhus, Fac Hlth Sci, DK-8000 Aarhus C, Denmark
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2002年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：653A / 653A
页数：1
相关论文
共 50 条
  • [31] Candesartan cilexetil: a new, long acting, effective angiotensin II type 1 receptor blocker
    Sever, P
    JOURNAL OF HUMAN HYPERTENSION, 1997, 11 : S91 - S95
  • [32] The Angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer
    Okazaki, Mitsuyoshi
    Fushida, Sachio
    Harada, Shinichi
    Tsukada, Tomoya
    Kinoshita, Jun
    Oyama, Katsunobu
    Tajima, Hidehiro
    Ninomiya, Itasu
    Fujimura, Takashi
    Ohta, Tetsuo
    CANCER LETTERS, 2014, 355 (01) : 46 - 53
  • [33] Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker for the prevention of type 2 diabetes mellitus?
    Chen, Ching-Chu
    Chiang, An-Na
    Hsieh, Min-Huang
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 90 (02) : E25 - E26
  • [34] Distribution of hemoglobin, concentration in patients with type 2 diabetes and nephropathy.
    Mohanram, A
    Zhang, J
    Shahinfar, S
    Keane, WF
    Brenner, BM
    Toto, RD
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 455A - 456A
  • [35] Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan
    Tsukuda, Kana
    Mogi, Masaki
    Li, Jian-Mei
    Iwanami, Jun
    Min, Li-Juan
    Sakata, Akiko
    Fujita, Teppei
    Iwai, Masaru
    Horiuchi, Masatsugu
    HYPERTENSION, 2007, 50 (06) : 1099 - 1105
  • [36] Angiotensin II type 1 receptor genotype and response to angiotensin II receptor blocker valsartan in early stage diabetic nephropathy
    Takei, Kako
    Kimura, Tomomi
    Miyazaki, Mitsuhiro
    Matsumoto, Ryuma
    muramatsu, Masaaki
    JOURNAL OF HYPERTENSION, 2006, 24 : 223 - 223
  • [37] The angiotensin receptor blocker, candesartan reduces atherosclerosis in a dose-dependent manner
    Johnstone, MT
    Perez, A
    Stewart, R
    Cole, D
    Weissberg, J
    Quist, W
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (02) : 294A - 294A
  • [38] COMBINED EFFECTS OF ANGIOTENSIN II RECEPTOR ANTAGONIST AND CALCIUM CHANNEL BLOCKER IN HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES
    Yokoi, T.
    Nakade, S.
    Masaki, H.
    Komiyama, Y.
    Masuda, M.
    Yoshika, M.
    Tsukaguchi, H.
    Takahashi, H.
    JOURNAL OF HYPERTENSION, 2010, 28 : E297 - E298
  • [39] Effects of candesartan, an angiotensin II receptor type I blocker, on atrial remodeling in spontaneously hypertensive rats
    Choisy, Stephanie C.
    Kim, Shang-Jin
    Hancox, Jules C.
    Jones, Sandra A.
    James, Andrew F.
    PHYSIOLOGICAL REPORTS, 2015, 3 (01): : 1 - 10
  • [40] Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE-inhibitor in diabetic nephropathy.
    Rossing, K
    Jacobsen, PK
    Pietraszek, L
    Parving, HH
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 601A - 601A
12345